Our Product Candidates

AVEO Oncology is committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates. Our product candidates include tivozanib, ficlatuzumab, AV-203 and AV-380.